First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jian Zhou, Hye Jin Choi, Masafumi Ikeda, Angela Lamarca, Do-Youn Oh, Tiziana Pressiani, Ho Yeong Lim, Hong Jae Chon, Hyung-Don Kim, Andrea Casadei Gardini, Ann-Lii Cheng, Ruifan Xie, Jinfeng Xiang, Rui Miao, Olivia Aoli, Sujatha Muralidharan, Osama E. Rahma, Rakesh Kumar, Ghassan K. Abou-Alfa
Institutions: Fudan University, Zhongshan Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, National Cancer Center Hospital East, Hospital Universitario Fundación Jiménez Díaz, Seoul National University, Seoul National University Hospital, IRCCS Humanitas Research Hospital, Samsung Medical Center, Sungkyunkwan University, CHA University Bundang Medical Center, CHA University, Asan Medical Center, University of Ulsan, Vita-Salute San Raffaele University, National Taiwan University, AstraZeneca (United Kingdom), AstraZeneca (United States), Memorial Sloan Kettering Cancer Center, Trinity College Dublin, Cornell University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410814959